![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: HDAC2 |
Gene summary for HDAC2 |
![]() |
Gene information | Species | Human | Gene symbol | HDAC2 | Gene ID | 3066 |
Gene name | histone deacetylase 2 | |
Gene Alias | HD2 | |
Cytomap | 6q21 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q92769 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3066 | HDAC2 | GSM4909281 | Human | Breast | IDC | 3.44e-02 | 2.93e-01 | 0.21 |
3066 | HDAC2 | GSM4909285 | Human | Breast | IDC | 9.19e-30 | 6.25e-01 | 0.21 |
3066 | HDAC2 | GSM4909286 | Human | Breast | IDC | 6.81e-04 | 3.76e-01 | 0.1081 |
3066 | HDAC2 | GSM4909287 | Human | Breast | IDC | 6.52e-06 | 3.19e-01 | 0.2057 |
3066 | HDAC2 | GSM4909293 | Human | Breast | IDC | 3.45e-05 | 3.26e-01 | 0.1581 |
3066 | HDAC2 | GSM4909296 | Human | Breast | IDC | 5.60e-13 | -2.83e-01 | 0.1524 |
3066 | HDAC2 | GSM4909297 | Human | Breast | IDC | 1.69e-11 | -1.28e-01 | 0.1517 |
3066 | HDAC2 | GSM4909302 | Human | Breast | IDC | 8.95e-09 | -2.84e-01 | 0.1545 |
3066 | HDAC2 | GSM4909311 | Human | Breast | IDC | 2.08e-21 | -2.20e-01 | 0.1534 |
3066 | HDAC2 | GSM4909312 | Human | Breast | IDC | 1.46e-09 | -9.16e-02 | 0.1552 |
3066 | HDAC2 | GSM4909319 | Human | Breast | IDC | 5.75e-26 | -2.92e-01 | 0.1563 |
3066 | HDAC2 | GSM4909320 | Human | Breast | IDC | 1.46e-06 | -2.79e-01 | 0.1575 |
3066 | HDAC2 | GSM4909321 | Human | Breast | IDC | 2.26e-12 | -2.26e-01 | 0.1559 |
3066 | HDAC2 | brca3 | Human | Breast | Precancer | 3.44e-04 | 3.18e-01 | -0.0263 |
3066 | HDAC2 | M2 | Human | Breast | IDC | 1.30e-10 | 5.28e-01 | 0.21 |
3066 | HDAC2 | NCCBC14 | Human | Breast | DCIS | 4.60e-09 | -2.16e-02 | 0.2021 |
3066 | HDAC2 | NCCBC5 | Human | Breast | DCIS | 4.33e-10 | -7.12e-02 | 0.2046 |
3066 | HDAC2 | NCCBC6 | Human | Breast | DCIS | 2.73e-06 | 5.13e-01 | 0.2095 |
3066 | HDAC2 | P1 | Human | Breast | IDC | 1.01e-13 | -1.51e-01 | 0.1527 |
3066 | HDAC2 | P2 | Human | Breast | IDC | 2.24e-05 | 2.71e-01 | 0.21 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004254216 | Endometrium | EEC | response to hydrogen peroxide | 41/2168 | 146/18723 | 4.12e-08 | 2.29e-06 | 41 |
GO:004851114 | Endometrium | EEC | rhythmic process | 67/2168 | 298/18723 | 5.86e-08 | 3.11e-06 | 67 |
GO:003459917 | Endometrium | EEC | cellular response to oxidative stress | 63/2168 | 288/18723 | 4.05e-07 | 1.58e-05 | 63 |
GO:003292212 | Endometrium | EEC | circadian regulation of gene expression | 22/2168 | 68/18723 | 4.49e-06 | 1.14e-04 | 22 |
GO:005110117 | Endometrium | EEC | regulation of DNA binding | 31/2168 | 118/18723 | 8.11e-06 | 1.81e-04 | 31 |
GO:007155914 | Endometrium | EEC | response to transforming growth factor beta | 54/2168 | 256/18723 | 8.25e-06 | 1.83e-04 | 54 |
GO:003461416 | Endometrium | EEC | cellular response to reactive oxygen species | 37/2168 | 155/18723 | 1.26e-05 | 2.55e-04 | 37 |
GO:000762314 | Endometrium | EEC | circadian rhythm | 46/2168 | 210/18723 | 1.37e-05 | 2.73e-04 | 46 |
GO:007156014 | Endometrium | EEC | cellular response to transforming growth factor beta stimulus | 52/2168 | 250/18723 | 1.81e-05 | 3.41e-04 | 52 |
GO:000223714 | Endometrium | EEC | response to molecule of bacterial origin | 68/2168 | 363/18723 | 3.96e-05 | 6.64e-04 | 68 |
GO:003249614 | Endometrium | EEC | response to lipopolysaccharide | 65/2168 | 343/18723 | 4.04e-05 | 6.75e-04 | 65 |
GO:007048216 | Endometrium | EEC | response to oxygen levels | 65/2168 | 347/18723 | 5.81e-05 | 9.03e-04 | 65 |
GO:001097513 | Endometrium | EEC | regulation of neuron projection development | 79/2168 | 445/18723 | 6.80e-05 | 1.01e-03 | 79 |
GO:000301213 | Endometrium | EEC | muscle system process | 79/2168 | 452/18723 | 1.16e-04 | 1.55e-03 | 79 |
GO:004876212 | Endometrium | EEC | mesenchymal cell differentiation | 47/2168 | 236/18723 | 1.35e-04 | 1.76e-03 | 47 |
GO:001072012 | Endometrium | EEC | positive regulation of cell development | 56/2168 | 298/18723 | 1.68e-04 | 2.10e-03 | 56 |
GO:005110016 | Endometrium | EEC | negative regulation of binding | 35/2168 | 162/18723 | 1.85e-04 | 2.26e-03 | 35 |
GO:009730516 | Endometrium | EEC | response to alcohol | 49/2168 | 253/18723 | 1.99e-04 | 2.42e-03 | 49 |
GO:003460516 | Endometrium | EEC | cellular response to heat | 19/2168 | 69/18723 | 2.27e-04 | 2.70e-03 | 19 |
GO:006048512 | Endometrium | EEC | mesenchyme development | 54/2168 | 291/18723 | 3.01e-04 | 3.37e-03 | 54 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa05031 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa052036 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa050311 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa0520312 | Breast | Precancer | Viral carcinogenesis | 27/684 | 204/8465 | 7.19e-03 | 4.06e-02 | 3.11e-02 | 27 |
hsa0501623 | Breast | IDC | Huntington disease | 103/867 | 306/8465 | 5.14e-30 | 4.17e-28 | 3.12e-28 | 103 |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa050312 | Breast | IDC | Amphetamine addiction | 18/867 | 69/8465 | 1.42e-04 | 1.36e-03 | 1.01e-03 | 18 |
hsa0491916 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0520322 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0522010 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
hsa0501633 | Breast | IDC | Huntington disease | 103/867 | 306/8465 | 5.14e-30 | 4.17e-28 | 3.12e-28 | 103 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa050313 | Breast | IDC | Amphetamine addiction | 18/867 | 69/8465 | 1.42e-04 | 1.36e-03 | 1.01e-03 | 18 |
hsa0491917 | Breast | IDC | Thyroid hormone signaling pathway | 23/867 | 121/8465 | 2.45e-03 | 1.69e-02 | 1.27e-02 | 23 |
hsa0520332 | Breast | IDC | Viral carcinogenesis | 34/867 | 204/8465 | 2.82e-03 | 1.86e-02 | 1.39e-02 | 34 |
hsa0522013 | Breast | IDC | Chronic myeloid leukemia | 15/867 | 76/8465 | 9.24e-03 | 4.37e-02 | 3.27e-02 | 15 |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC2 | SNV | Missense_Mutation | c.502N>T | p.His168Tyr | p.H168Y | Q92769 | protein_coding | deleterious(0.04) | possibly_damaging(0.828) | TCGA-A7-A0DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
HDAC2 | SNV | Missense_Mutation | c.523N>A | p.Asp175Asn | p.D175N | Q92769 | protein_coding | deleterious(0.03) | probably_damaging(0.915) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
HDAC2 | deletion | Nonsense_Mutation | c.459_463delNNNNN | p.Tyr153Ter | p.Y153* | Q92769 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | |||
HDAC2 | SNV | Missense_Mutation | novel | c.691G>A | p.Asp231Asn | p.D231N | Q92769 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HDAC2 | deletion | Frame_Shift_Del | novel | c.883_884delNN | p.Pro295IlefsTer13 | p.P295Ifs*13 | Q92769 | protein_coding | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
HDAC2 | SNV | Missense_Mutation | c.875N>G | p.Phe292Cys | p.F292C | Q92769 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
HDAC2 | SNV | Missense_Mutation | c.1229N>T | p.Ala410Val | p.A410V | Q92769 | protein_coding | tolerated(0.32) | benign(0.423) | TCGA-F4-6703-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
HDAC2 | SNV | Missense_Mutation | c.230T>C | p.Leu77Pro | p.L77P | Q92769 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-NH-A50T-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
HDAC2 | SNV | Missense_Mutation | novel | c.1001N>G | p.Tyr334Cys | p.Y334C | Q92769 | protein_coding | deleterious(0) | possibly_damaging(0.761) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
HDAC2 | SNV | Missense_Mutation | novel | c.1271N>T | p.Ser424Phe | p.S424F | Q92769 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | 2-ENE-VALPROATE | CHEMBL117487 | 17566732 | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051807 | SCRIPTAID | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | BELINOSTAT | BELINOSTAT | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051797 | APICIDIN | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | PAZOPANIB | PAZOPANIB | 28221861 | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | PRACINOSTAT | PRACINOSTAT | ||
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051798 | BELINOSTAT | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | SODIUM PHENYLBUTYRATE | ||
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | VORINOSTAT | VORINOSTAT | 24694055,19344175,19966789,26211462,23622981,22260166,17447750,20491440,21548582,24074025,23672185,19084294 | |
3066 | HDAC2 | DRUGGABLE GENOME, CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR | PANOBINOSTAT | PANOBINOSTAT |
Page: 1 2 3 4 5 6 7 8 9 10 11 |